Tricor patent settlement allows Teva generic in 2011 at the earliest
This article was originally published in Scrip
Executive Summary
Abbott Laboratories has settled US patent litigation with Teva Pharmaceutical Industries, allowing the generics firm to market a competitor to its cholesterol-lowering Tricor (fenofibrate) 145mg tablets in 2011 at the earliest.